Zanamivir (Dectova®) which is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/08/2019|
|Rapid review completed||17/10/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that zanamivir (Dectova®) be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.